COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy
Q Zhang, R Xiang, S Huo, Y Zhou, S Jiang… - Signal transduction and …, 2021 - nature.com
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …
Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
MJ Levin, A Ustianowski, S De Wit… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Abstract The SARS-CoV-2 B. 1.1. 529 (Omicron) variant contains 15 mutations of the
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
receptor-binding domain (RBD). How Omicron evades RBD-targeted neutralizing antibodies …
An infectious SARS-CoV-2 B. 1.1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
The emergence of the highly transmissible B. 1.1. 529 Omicron variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody …
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
PJ Halfmann, S Iida, K Iwatsuki-Horimoto, T Maemura… - Nature, 2022 - nature.com
The recent emergence of B. 1.1. 529, the Omicron variant,, has raised concerns of escape
from protection by vaccines and therapeutic antibodies. A key test for potential …
from protection by vaccines and therapeutic antibodies. A key test for potential …
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
YM Loo, PM McTamney, RH Arends… - Science translational …, 2022 - science.org
Despite the success of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines, there remains a need for more prevention and treatment options for individuals …
vaccines, there remains a need for more prevention and treatment options for individuals …
Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
Antibody-based therapeutics and vaccines are essential to combat COVID-19 morbidity and
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
mortality after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
COVID-19 pandemic. Rapidly spreading SARS-CoV-2 variants may jeopardize newly …
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Understanding the molecular basis for immune recognition of SARS-CoV-2 spike
glycoprotein antigenic sites will inform the development of improved therapeutics. We …
glycoprotein antigenic sites will inform the development of improved therapeutics. We …